GlassScriptPhysician profile
Eunsun Kim
NPI 1508408899
$5,159.98
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,577 · 2022: $1,387 · 2023: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,097 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,096.67 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $437.31 | 2021-2023 | Padcev, Xospata |
| Seagen INC. | $433.27 | 2021-2023 | Tukysa, Adcetris |
| Astrazeneca Pharmaceuticals LP | $413.51 | 2021-2023 | Calquence |
| Pharmacyclics LLC, An Abbvie Company | $363.78 | 2021-2023 | Epkinly, Imbruvica |
| Merck Sharp & Dohme LLC | $362.87 | 2021-2023 | Keytruda, Lynparza |
| Amgen INC. | $304.86 | 2021-2023 | Nplate, Vectibix |
| Novartis Pharmaceuticals Corporation | $294.08 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $261.79 | 2021-2022 | |
| Pfizer INC. | $196.35 | 2021-2023 | |
| Celgene Corporation | $179.14 | 2021-2023 | Opdualag |
| Eisai INC. | $176.42 | 2021-2023 | |
| Lilly USA, LLC | $166.74 | 2021-2023 | Verzenio, Jaypirca |
| Janssen Biotech, INC. | $158.68 | 2021-2023 | Erleada |
| Genzyme Corporation | $134.96 | 2021-2023 | |
| Incyte Corporation | $112.25 | 2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eunsun Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.